Hsk42360-na
A drug being studied in colorectal cancer trials. It appears in 2 clinical trials.
What it is
HSK42360-Na is an investigational medication currently being studied in clinical trials. It is being evaluated as a potential treatment for solid tumors, specifically those with a BRAF V600 mutation. The trials are in the early phase (Phase 1), focusing on determining the safe dosage and how the drug is processed by the body (pharmacokinetics) and its effects on the body (pharmacodynamics). It is taken orally. This drug is not yet approved for use in colorectal cancer or any other condition.
How it works
HSK42360-Na is being investigated for its potential activity against tumors that have a specific genetic change called a BRAF V600 mutation. The exact way HSK42360-Na works is still being studied, but it is designed to target processes within cancer cells. The specific molecular target is being characterized in clinical trials.
Common side effects
Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.
Guides that may help
Written for patients and families, in plain language.